{"brief_title": "Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis", "brief_summary": "OBJECTIVES: I. Assess the safety and efficacy of 4-aminosalicylic acid in patients with mildly to moderately severe ulcerative colitis.", "detailed_description": "PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by extent of disease. Patients are randomly assigned to oral 4-aminosalicylic acid (4-ASA) or placebo administered daily for 6 weeks. Optional 4-ASA is available to all patients for up to 1 year. Concurrent therapy with low-dose sulfasalazine, prednisone, or equivalent is allowed.", "condition": ["Ulcerative Colitis"], "intervention_type": ["Drug"], "intervention_name": ["-aminosalicylic acid"], "criteria": "PROTOCOL ENTRY CRITERIA: - Mildly to moderately severe ulcerative colitis - Patient age: 18 to 80", "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "keyword": "ulcerative colitis", "mesh_term": ["Ulcer", "Colitis, Ulcerative", "Colitis", "Aminosalicylic Acid"], "id": "NCT00004810"}